Zephyr AI, a company leveraging large complex data and proprietary algorithms to discover new insights and opportunities for precision medicine and drug development, has secured $15.5M in Series A funding.
The company's work spans personalized medicine, drug discovery, drug rescue, and clinical decision support. Zephyr AI partners with leading health systems, health insurance plans, and biotechnology pioneers, aiming to improve quality, outcomes, and costs through its advanced analytical approach.
.png&w=3840&q=75)
